Key result
Novel SLASH score outperforms SLAC score for predicting 6-month AF recurrence after electrical cardioversion.
Why the study?
The SLAC score provides only moderate prediction of 6-month AF recurrence after ECV, creating a need for improved risk stratification.
Does the SLASH score improve prediction of 6-month atrial fibrillation recurrence after electrical cardioversion compared to the SLAC score?
Cohort (n=361)
No
Does the SLASH score improve prediction of 6-month atrial fibrillation recurrence after electrical cardioversion compared to the SLAC score?
Effect estimate: AUC 0.78
The newly developed SLASH score offers superior discrimination over the SLAC score for predicting 6-month atrial fibrillation recurrence after electrical cardioversion, potentially improving risk stratification.
May improve AF recurrence risk stratification post-cardioversion; extends SLAC with superior cohort performance.
Background Predicting atrial fibrillation (AF) recurrence after electrical cardioversion (ECV) is challenging. The SLAC score predicts 6‐month recurrence but lacked robust external validation. We aimed to externally validate the SLAC score and develop an improved predictive model. Methods We conducted a single‐center retrospective study of patients who underwent successful ECV for AF between 2015 and 2020. Patients with atrial flutter, complex congenital heart disease or early AF ablation were excluded. The primary outcome was AF recurrence at 6 months. SLAC score performance was tested, and multivariable logistic regression was used to develop the SLASH score. Discrimination was assessed with the area under the curve (AUC), calibration with Hosmer–Lemeshow testing, and internal validation with bootstrapping. Results Of 361 patients (mean age 66 ± 12 years, 61% male), 53.7% experienced AF recurrence in 6 months. Median SLAC scores were higher in recurrence patients (7 vs. 2). The SLAC score demonstrated moderate discrimination (AUC 0.70), improved with a cutoff ≥ 6 (AUC 0.72). Independent predictors of recurrence included left atrial volume index ≥ 40 mL/m 2 , prior stroke/TIA, heart rate > 70 bpm, smoking history, and absence of post‐ECV antiarrhythmic therapy. These were incorporated into the SLASH score (0–8 points), which demonstrated improved discrimination (AUC 0.78). Recurrence rates were 16.1%, 65.4%, and 78.5% in low‐, moderate‐, and high‐risk groups, respectively, with acceptable calibration (Hosmer–Lemeshow p = 0.18). Conclusion The SLAC score provides moderate prediction of 6‐month AF recurrence after ECV. The SLASH score showed superior performance and may improve risk stratification and rhythm management. Prospective validation is warranted.
No takes yet. Share an insight, caveat, or question.
Thangjui et al. (2026) conducted a cohort in Atrial fibrillation (n=361). SLASH score vs. SLAC score was evaluated on Atrial fibrillation recurrence at 6 months (AUC 0.78). The SLASH score demonstrated improved discrimination (AUC 0.78) for predicting 6-month atrial fibrillation recurrence after electrical cardioversion compared to the SLAC score (AUC 0.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: